Resolution of hyphaema following intracameral injection of tenecteplase in a Stock Horse

Aust Vet J. 2013 Jan-Feb;91(1-2):31-4. doi: 10.1111/avj.12003. Epub 2012 Dec 2.

Abstract

Intracameral injection of tissue plasminogen activator has been suggested as a means of hastening the clearance of blood from the anterior chamber and reducing the risk of synechia and fibrotic membrane formation in horses with hyphaema. The following report describes a case of ocular trauma in which intracameral injection of tenecteplase (TNK), a new-generation plasminogen activator, resulted in rapid resolution of hyphaema and successful outcome. However, a large dose (1 mg) was administered and may have been associated with retinopathy and keratopathy. TNK may be an effective treatment for equine hyphaema and further controlled clinical or experimental studies are required to determine its efficacy and safety profiles.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Fibrinolytic Agents / therapeutic use*
  • Head Injuries, Closed / complications
  • Head Injuries, Closed / veterinary
  • Horse Diseases / drug therapy*
  • Horse Diseases / etiology
  • Horses
  • Hyphema / drug therapy
  • Hyphema / etiology
  • Hyphema / veterinary*
  • Male
  • Tenecteplase
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
  • Tenecteplase